NATIVE
112 evidence topics · 14 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Study objective in the protocol
Objective stated in the design paper
“NATIVE study (EudraCT: 2016-001979-70, NCT: NCT03008070) aims to assess the safety and the efficacy of a 24-week treatment with lanifibranor (800 and 1200 mg/day) in adult non-cirrhotic NASH patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aim of the trial in the published report
Location and study date
Study dates in the ClinicalTrials.gov record
“Study Start (Actual) 2017-02-07” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2020-02-20” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2020-03-16” (opens the source at this quote in a new tab)
“Results First Posted 2021-04-12” (opens the source at this quote in a new tab)
Registered locations
Countries and screening period in the published report
Planned sites and study period in the protocol
Study design
Phase 2b, randomized, double-blind, placebo-controlled design
Design summary in the design paper
“NATIVE is a Phase 2b randomised, placebo-controlled, double-blind, parallel-assignment, dose-range study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study will evaluate the efficacy of a 24-week treatment of NASH with lanifibranor based on histological evaluations (SAF score) by biopsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Enrollment | “Enrollment (Actual) 247” |
Treatment groups, blinding, and study duration in the ClinicalTrials.gov record
Study arms, visit schedule, and selection period in the protocol
Randomization procedure in the protocol
Screening biopsy and centralized histology reading in the protocol
Rationale for the placebo comparator and the 6-month duration in the protocol
Trial oversight and sponsor role
Eligibility criteria
Key eligibility criteria in the published report
No fibrosis-stage inclusion criterion other than the exclusion of cirrhosis
“Eligible adult patients with a confirmed histological diagnosis of NASH should have a SAF Activity score of 3 or 4 (>2) and a SAF Steatosis score ≥ 1. There is no specific criterion related to the fibrosis score except that patients with cirrhosis (F4) were excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria in the ClinicalTrials.gov record
Laboratory criteria for compensated liver disease in the protocol
“ALT < 10xULN” (opens the source at this quote in a new tab)
“Platelets > 100 10^9/L (100 10^3/µL)” (opens the source at this quote in a new tab)
“Albumin > 36 g/L (3.6 g/dL)” (opens the source at this quote in a new tab)
“International Normalized Ratio (INR) < 1.4” (opens the source at this quote in a new tab)
Prohibited concomitant medications in the protocol
Permitted antidiabetic and lipid-lowering medications in the protocol
Treatment
Doses, schedule, and duration in the published report
Arms in the ClinicalTrials.gov record
| Arm | Description |
|---|---|
| Experimental: IVA337 1200mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Experimental: IVA337 800mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Placebo Comparator: Placebo | “Placebo to match, once a day (Quaque Die, QD) with food” |
Tablets, kits, and administration with breakfast in the protocol
“Placebo Kit: Morning (P+P+P)” (opens the source at this quote in a new tab)
“800 mg Kit: Morning (P+A+A)” (opens the source at this quote in a new tab)
“1200 mg Kit: Morning (A+A+A)” (opens the source at this quote in a new tab)
“Dosage modifications are not permitted.” (opens the source at this quote in a new tab)
Dose selection and food intake rationale in the protocol
Treatment compliance measures in the protocol
Study outcomes
Rationale for using SAF activity score decrease of at least 2 points without worsening of fibrosis as the primary endpoint
Primary end point definition in the published report
Primary outcome measure in the ClinicalTrials.gov record
Primary endpoint and responder definition in the protocol
Primary endpoint in the design paper
“The primary efficacy endpoint is a 2-point reduction in the activity part of the Steatosis Activity Fibrosis (SAF) histological score (combining inflammation and ballooning) without worsening of fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for scoring activity separately from steatosis in the published report
Justification for the SAF activity score in the protocol
Liver histology as the efficacy measure in FDA and EMA approved phase 3 trials, as stated in the protocol
Regulatory context for histologic surrogate end points in the published report
Secondary histologic and nonhistologic end points in the published report
Exploratory end points, including quality of life, in the published report
Quality-of-life questionnaires assessed in the protocol
Registered secondary end point definitions for NASH resolution and fibrosis improvement
Histology reading by one blinded pathologist
Protocol version 5.0, July 2019: secondary endpoints updated
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power in the protocol
Randomized participants and per-protocol population in the published report
Missing week 24 biopsies by group in the full analysis population
Enrollment in the ClinicalTrials.gov record
Participants analyzed at baseline in the registry results
Description of analysis sets
Full analysis, safety, and per-protocol populations in the published report
Analysis sets defined in the protocol
Primary analysis method and missing-data rule in the protocol
Multiplicity adjustment, multiple imputation, and sensitivity analyses in the published report
Analysis of continuous secondary end points in the published report
Results
Participant disposition
Screening, randomization, and completion in the published report
Participant flow and reasons for not completing in the registry results
| Milestone or reason | Lanifibranor 1200mg | Lanifibranor 800mg | Placebo |
|---|---|---|---|
| Started | “83” | “83” | “81” |
| Completed | “77” | “77” | “74” |
| Not completed | “6” | “6” | “7” |
| Adverse event | “3” | “3” | “3” |
| Lost to follow-up | “1” | “1” | “0” |
| Non compliance | “0” | “1” | “1” |
| Use of prohibited drug | “0” | “0” | “2” |
| Withdrawal by patient and adverse event non fatal | “0” | “1” | “0” |
| Withdrawal by subject | “2” | “0” | “1” |
Baseline characteristics
Baseline characteristics summarized in the published report
Demographic and clinical characteristics at baseline, full analysis population
Baseline characteristics of participants with type 2 diabetes
Selection of more severe disease through the SAF-A criterion
Antidiabetic medication, prediabetes, obesity, and statin use in the enrolled population
“Of 247 patients enrolled, 228 completed the study; mean age was 54 years, 58% were female, 94% were Caucasian, mean body mass index (BMI) was 33 kg/m2; 42% (n = 103) had T2D. Of these, 83% received metformin (alone or in combination anti-diabetic treatment), 22%, sulphonylurea; 11%, dipeptidyl peptidase-4 inhibitor; 7% sodium-glucose cotransporter-2 inhibitor medication; 13% had no antidiabetic treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 144 patients without T2D, 47 (33%) had prediabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 20% of patients took statins (22%, 22%, 16% with lanifibranor 1200 mg, 800 mg, and placebo respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age categories and race in the registry results
| Characteristic | IVA337 1200mg | IVA337 800mg | Placebo | Total |
|---|---|---|---|---|
| Age between 18 and 65 years | “67” | “69” | “63” | “199” |
| Age 65 years or older | “16” | “14” | “18” | “48” |
| American Indian or Alaska Native | “0” | “0” | “2” | “2” |
| Asian | “2” | “1” | “2” | “5” |
| Native Hawaiian or Other Pacific Islander | “0” | “1” | “0” | “1” |
| Black or African American | “3” | “1” | “3” | “7” |
| White | “78” | “80” | “74” | “232” |
Region of enrollment in the registry results
| Country | IVA337 1200mg | IVA337 800mg | Placebo | Total |
|---|---|---|---|---|
| Bulgaria | “17” | “16” | “22” | “55” |
| France | “15” | “15” | “9” | “39” |
| United States | “13” | “11” | “12” | “36” |
| Belgium | “10” | “11” | “11” | “32” |
| Australia | “3” | “7” | “3” | “13” |
| Germany | “7” | “3” | “3” | “13” |
| Spain | “3” | “4” | “5” | “12” |
| Czechia | “3” | “2” | “3” | “8” |
| Canada | “3” | “1” | “4” | “8” |
| United Kingdom | “3” | “2” | “2” | “7” |
| Mauritius | “2” | “3” | “2” | “7” |
| Poland | “1” | “2” | “3” | “6” |
| Italy | “3” | “1” | “1” | “5” |
| Switzerland | “0” | “3” | “1” | “4” |
| Austria | “0” | “1” | “0” | “1” |
| Slovenia | “0” | “1” | “0” | “1” |
Efficacy results
Primary endpoint: full analysis population with multiple imputation
Primary endpoint: nonresponder imputation, complete-case, per-protocol, and F2 or F3 fibrosis analyses
Key secondary histologic endpoints: multiple imputation
Histologic endpoints in participants with F2 or F3 fibrosis: journal report
Primary and key secondary histologic endpoints: ITT and per-protocol populations, company topline release
| Endpoint at week 24 | ITT placebo | ITT lanifibranor 800 mg | ITT lanifibranor 1200 mg | PP placebo | PP lanifibranor 800 mg | PP lanifibranor 1200 mg |
|---|---|---|---|---|---|---|
| Number of participants | “(N = 81)” | “(N = 83)” | “(N = 83)” | “(N = 62)” | “(N = 63)” | “(N = 69)” |
| Decrease of at least 2 points in SAF activity score (primary) | “27%” | “41% P=0.061” | “49% P=0.004*” | “34%” | “51% P=0.058” | “55% P=0.015*” |
| Resolution of NASH and no worsening of fibrosis | “19%” | “33% P=0.043*” | “45% P<0.001*” | “23%” | “40% P=0.039*” | “49% P=0.002*” |
| Improvement of fibrosis by at least one stage and no worsening of NASH | “24%” | “28% P=0.53” | “42% P=0.011*” | “29%” | “32% P=0.75” | “46% P=0.04*” |
| Resolution of NASH and improvement of fibrosis | “7%” | “21% P=0.017*” | “31% P<0.001*” | “10%” | “24% P=0.036*” | “33% P=0.001*” |
| Decrease of at least 2 points in NAS and no worsening of fibrosis | “32%” | “52% P=0.01*” | “64% P<0.001*” | “40%” | “62% P=0.02*” | “71% P<0.001*” |
Resolution of NASH without worsening of fibrosis in participants with F2 or F3 fibrosis: ITT and per-protocol populations, company topline release
| Population | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg |
|---|---|---|---|
| ITT, F2 or F3 fibrosis | “9%” | “34% P=0.011*” | “44% P<0.001*” |
| Per protocol, F2 or F3 fibrosis | “11%” | “40% P=0.016*” | “51% P<0.001*” |
Histologic endpoints: participants with a response, missing data counted as nonresponse, registry results
| Outcome measure at 24 weeks (participants with a response) | IVA337 1200mg | IVA337 800mg | Placebo |
|---|---|---|---|
| Overall number of participants analyzed | “83” | “83” | “81” |
| SAF-A decrease of at least 2 points with no worsening of CRN-F (primary) | “41” | “34” | “22” |
| NASH improvement (NAS decrease of at least 2 points without worsening of fibrosis) | “53” | “43” | “26” |
| NASH resolution and no worsening of fibrosis | “37” | “27” | “15” |
| Improvement of fibrosis by at least 1 stage and no worsening of NASH | “35” | “23” | “19” |
| Resolution of NASH and improvement of fibrosis by at least 1 stage | “26” | “17” | “6” |
| Activity (SAF-A) improvement | “62” | “54” | “40” |
| Steatosis (CRN-S) improvement | “54” | “46” | “21” |
| Lobular inflammation (CRN-I) improvement | “43” | “34” | “30” |
| Hepatocyte ballooning (CRN-B) improvement | “60” | “54” | “37” |
| Fibrosis (CRN-F) improvement | “36” | “28” | “22” |
| Modified Ishak fibrosis (ISHAK-F) improvement | “41” | “32” | “25” |
Liver enzymes: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Alanine aminotransferase, U/liter | “−24.54 (−32.06 to −17.01)” | “−26.08 (−33.67 to −18.50)” | “−1.40 (−9.04 to 6.25)” |
| Aspartate aminotransferase, U/liter | “−12.04 (−18.29 to −5.79)” | “−15.11 (−21.43 to −8.80)” | “−0.08 (−6.43 to 6.26)” |
| γ-Glutamyltransferase, U/liter | “−27.87 (−38.88 to −16.86)” | “−43.38 (−54.46 to −32.29)” | “4.41 (−6.76 to 15.58)” |
Lipids and apolipoproteins: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Total cholesterol, mmol/liter | “−0.07 (−0.22 to 0.07)” | “−0.02 (−0.17 to 0.13)” | “0.01 (−0.14 to 0.16)” |
| Fasting HDL cholesterol, mmol/liter | “0.11 (0.06 to 0.15)” | “0.16 (0.12 to 0.21)” | “0.01 (−0.04 to 0.05)” |
| Fasting LDL cholesterol, mmol/liter | “0.03 (−0.11 to 0.16)” | “0.03 (−0.11 to 0.16)” | “0.01 (−0.12 to 0.15)” |
| Fasting triglycerides, mmol/liter | “−0.44 (−0.61 to −0.27)” | “−0.49 (−0.66 to −0.31)” | “0.06 (−0.12 to 0.23)” |
| Fasting apolipoprotein A1, mg/dl | “−4.39 (−8.64 to −0.13)” | “−0.29 (−4.61 to 4.04)” | “0.03 (−4.27 to 4.33)” |
| Fasting apolipoprotein B, mg/dl (exploratory) | “−11.61 (−15.64 to −7.57)” | “−11.51 (−15.61 to −7.41)” | “−1.85 (−5.79 to 2.09)” |
| Fasting apolipoprotein C3, μg/dl (exploratory) | “−9.98 (−17.74 to −2.22)” | “−8.08 (−16.02 to −0.13)” | “10.31 (2.67 to 17.94)” |
Glycemic markers and insulin resistance: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Fasting glucose, mmol/liter | “−0.60 (−0.83 to −0.37)” | “−0.78 (−1.01 to −0.55)” | “0.24 (0.01 to 0.47)” |
| Glycated hemoglobin, % | “−0.41 (−0.51 to −0.32)” | “−0.38 (−0.47 to −0.28)” | “0.07 (−0.02 to 0.17)” |
| Fasting insulin, pmol/liter | “−114.91 (−138.09 to −91.73)” | “−118.66 (−141.66 to −95.67)” | “−35.7 (−58.59 to −12.82)” |
| Fasting HOMA-IR index score | “−5.46 (−6.60 to −4.32)” | “−5.79 (−6.92 to −4.65)” | “−1.47 (−2.59 to −0.35)” |
Glycemic markers in participants with type 2 diabetes: journal report
Glycemic markers and adiponectin by diabetes status: mean absolute change at week 24, congress poster
| Parameter | T2DM, lanifibranor 800 mg | T2DM, lanifibranor 1200 mg | T2DM, placebo | No T2DM, lanifibranor 800 mg | No T2DM, lanifibranor 1200 mg | No T2DM, placebo |
|---|---|---|---|---|---|---|
| Fasting plasma glucose, mmol/L | “−1.71” | “−0.88” | “+0.29” | “−0.49” | “−0.39” | “+0.16” |
| HbA1c, % | “−0.60” | “−0.72” | “+0.10” | “−0.21” | “−0.25” | “+0.08” |
| HOMA index | “−10.62” | “−5.52” | “−0.60” | “−3.42” | “−7.27” | “+0.11” |
| Adiponectin, fold increase | “4.12” | “4.44” | “1.11” | “3.62” | “4.54” | “1.00” |
Adiponectin and inflammatory markers: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Adiponectin, μg/ml | “17.12 (14.29 to 19.96)” | “11.95 (8.97 to 14.94)” | “−0.35 (−3.20 to 2.50)” |
| High-sensitivity CRP, mg/liter | “−1.37 (−2.28 to −0.46)” | “−2.05 (−2.97 to −1.13)” | “0.11 (−0.81 to 1.03)” |
| Fibrinogen, g/liter | “−0.10 (−0.24 to 0.05)” | “−0.17 (−0.32 to −0.02)” | “0.02 (−0.12 to 0.17)” |
| α2-Macroglobulin, g/liter | “0.13 (0.04 to 0.22)” | “0.15 (0.06 to 0.24)” | “0.05 (−0.04 to 0.13)” |
| Haptoglobin, g/liter | “−0.07 (−0.13 to 0)” | “−0.05 (−0.12 to 0.01)” | “0.05 (−0.01 to 0.12)” |
Noninvasive tests of fibrosis, apoptosis, and steatosis: completers in the full analysis population
| Change from baseline in exploratory end points (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Pro-C3, μg/liter | “−1.79 (−3.07 to −0.52)” | “−3.93 (−5.26 to −2.61)” | “−1.01 (−2.30 to 0.28)” |
| TIMP-1 to MMP-2 ratio | “−0.75 (−0.93 to −0.57)” | “−0.69 (−0.88 to −0.50)” | “−0.11 (−0.29 to 0.08)” |
| Cytokeratin 18 M30, pmol/liter | “−315.55 (−441.55 to −189.55)” | “−331.71 (−463.78 to −199.65)” | “−105.03 (−232.86 to 22.80)” |
| Enhanced Liver Fibrosis test score | “0.11 (−0.04 to 0.26)” | “−0.19 (−0.35 to −0.04)” | “−0.08 (−0.23 to 0.06)” |
| Fibrosis-4 index score | “0.03 (−0.13 to 0.19)” | “0 (−0.17 to 0.16)” | “−0.03 (−0.19 to 0.13)” |
Cardiometabolic secondary and post hoc analyses: scope and multiplicity
“This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No multiplicity adjustments were performed for the analyses presented in this paper, that are considered exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limitations may include the fact that patients who meet study entry criteria may not represent all patients seen in varying practice environments; analyses were post-hoc of available data” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulin resistance and glycemic control: adjusted mean difference versus placebo at end of treatment
“Fasting insulin levels (FIL) significantly decreased with lanifibranor in the overall population; adjusted mean difference versus placebo [AMD] at end of treatment [EOT] was −79 pmol/L (95% confidence interval [CI]: −112 to −47, p < 0.001) with lanifibranor 1200 mg; −83 pmol/L (95%CI: −115 to −51, p < 0.001) with 800 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, AMD was −0.8 mmol/L (95%CI: −1.2 to −0.5, p < 0.001) with 1200 mg and −1.0 mmol/L (95%CI: −1.4 to −0.7, p < 0.001) with 800 mg. With T2D, AMD in hemoglobin A1c (HbA1c) at EOT was −0.7% (95%CI: −1.0 to −0.4, p < 0.001) in both active arms. Overall, HbA1c was −0.5% (95%CI: −0.6 to −0.3, p < 0.001) with both lanifibranor 1200 mg and 800 mg (Table 1, Fig. 1F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glycemic status in participants with prediabetes or normoglycemia at baseline: post hoc analysis
“With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, among 83 patients with normoglycemia at baseline, 0% with lanifibranor 1200 mg and 800 mg progressed to prediabetes at EOT, versus 26% (95%CI: 10 to 41, both p < 0.01) in the placebo arm (Supplementary Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further post-hoc analyses, i.e., not pre-specified in the SAP, included: the effects of therapy in the subgroups of patients with and without overt T2D; in patients with prediabetes at baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lipids and apolipoproteins: adjusted mean difference versus placebo at end of treatment
“Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 109 patients with high baseline TG values (>1.7 mmol/L, 150.5 mg/dL), 60% and 70% on lanifibranor 1200 mg and 800 mg, respectively, improved to low-risk TG levels of ≤1.7 mmol/L at EOT, versus 27% on placebo (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lanifibranor significantly reduced APO-B with an AMD at EOT of −10 mg/dL (95%CI: −15 to −4, p < 0.001) with both doses (Table 1, Fig. 1D)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic inflammation and ferritin: adjusted mean difference versus placebo at end of treatment
“With lanifibranor 1200 mg and 800 mg respectively, AMD at EOT was −1.5 mg/L (95%CI: −2.8 to −0.2, p = 0.026) and −2.2 mg/L (95%CI: −3.5 to −0.9, p = 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At EOT, levels decreased significantly with lanifibranor (AMD at EOT: −84.2 µg/L [95%CI: −125.2 to –43.3], −71.8 µg/L [95%CI: −112.6 to −31.0] for lanifibranor 800 mg and 1200 mg, respectively, both p < 0.001), but were unchanged with placebo (Table 1, Fig. 1H).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure: adjusted mean difference versus placebo at end of treatment
“From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]). Systolic BP did not change significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic steatosis by histology and controlled attenuation parameter
“Histological steatosis improved significantly at EOT with lanifibranor versus placebo, with more than 35% of patients improving by at least 2 grades with lanifibranor versus 5% with placebo (Fig. 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Controlled attenuation parameter (CAP™) similarly decreased significantly at EOT with lanifibranor (AMD at EOT was −23 dB/m [95%CI: −41 to −5, p = 0.012] with 1200 mg and −16 dB/m [95%CI: −33 to 1, p = 0.070] with 800 mg [Table 1]) but not with placebo (Fig. 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic and hepatic markers by weight change group: post hoc analysis
“In pooled lanifibranor arms, all CMH markers, i.e., steatosis, HOMA-IR, FIL, lipids (HDL-C, TG, APO-B, APO-C3, APO-B/APO-A), FG, hs-CRP, ferritin and DBP, as well as liver tests (ALT, AST, gamma-glutamyl transferase [GGT]), improved to the same degree in the three weight-change groups. In contrast, placebo-treated patients with increased weight at EOT had unchanged or worsening values of these markers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further post-hoc analyses, i.e., not pre-specified in the SAP, included” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the correlation between weight changes (both continuous and by weight-change group, i.e., <2.5%, 2.5−5% and ≥5% increase from baseline) under lanifibranor and placebo, separately, and improvement in CMH markers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adiponectin response and histologic improvement
“Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase. With placebo only 10% had moderate, and none high increase (Supplementary Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Absolute and categorical (fold change) adiponectin increase also correlated with improvement of liver histological endpoints for disease activity, i.e., CRN-NAFLD activity score (NAS) and individual activity components (ballooning and inflammation), and with improvement in fibrosis stage (38% versus 57% for adiponectin increase ≤4- versus >4-fold, respectively) (Supplementary Table 8, Fig. 5A−D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic markers in obese and non-obese participants
“Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1). Overall, the effects of lanifibranor therapy versus placebo on markers of CMH and on liver tests were similar for obese and non-obese patients (Supplementary Table 13).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adiponectin fold change at end of treatment by arm and relation to weight change: congress poster
| Fold adiponectin at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
|---|---|---|---|---|
| Number of participants | “72” | “66” | “73” | “139” |
| Mean (SD) | “1.1 ± 0.3” | “3.8 ± 3.1” | “4.5 ± 3.5” | “4.2 ± 3.3” |
| Unchanged | “65 (90%)” | “9 (14%)” | “4 (5%)” | “13 (9%)” |
| Fold 1.5 to 4 | “7 (10%)” | “38 (58%)” | “38 (52%)” | “76 (55%)” |
| Fold more than 4 | “0 (0.0%)” | “19 (29%)” | “31 (42%)” | “50 (36%)” |
Serum biomarker signatures of histologic response: pooled lanifibranor arms
“Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142). A panel of 65 biomarkers were evaluated by assessing baseline and absolute as well as relative changes at the end of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The biomarkers included in E1 score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2 score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine, and alanine aminotransferase), and E3 score (baseline cytokeratin 18 Fragment M65 and gamma-glutamyl transferase; delta of aspartate aminotransferase, insulin, and urea) represented metabolic, apoptotic, and fibrosis aspects of the disease. These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results from this analysis show evidence that baseline values and changes in selected serum biomarkers can aid in predicting histologic response in MASH under lanifibranor treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver sinusoidal endothelial cell capillarisation (CD34 staining) at baseline and week 24
“Among the latter, 173 patients had baseline liver tissue available for CD34 staining, including 163 with liver tissue also available at week 24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A). Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C). Patients with lanifibranor treatment had less worsening of lobular score (placebo: 39.6%, lanifibranor 800 mg: 18.5%, lanifibranor 1,200 mg: 23.2%; p = 0.028, Fig. 5F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Histologic and metabolic response by PNPLA3 genotype: congress poster
Health-related quality of life and patient-reported outcomes
SF-36 and Flinders Fatigue Scale at week 24
Safety results
Adverse event overview: full analysis population, treatment period
| Event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
|---|---|---|---|
| At least 1 adverse event | “62 (75)” | “59 (71)” | “50 (62)” |
| Mild | “54 (65)” | “51 (61)” | “42 (52)” |
| Moderate | “28 (34)” | “20 (24)” | “22 (27)” |
| Severe | “3 (4)” | “3 (4)” | “3 (4)” |
| Adverse event related to active drug or placebo, as assessed by the investigator | “23 (28)” | “25 (30)” | “19 (23)” |
| Adverse event that led to permanent discontinuation of the trial regimen | “3 (4)” | “4 (5)” | “3 (4)” |
| Adverse event related to active drug or placebo that led to discontinuation | “2 (2)” | “1 (1)” | “2 (2)” |
| Serious adverse event | “7 (8)” | “3 (4)” | “3 (4)” |
| Death | “0” | “0” | “0” |
| Serious adverse event related to active drug or placebo | “0” | “0” | “2 (2)” |
| Serious postprocedural condition linked to biopsy procedure | “3 (4)” | “1 (1)” | “0” |
Most frequent adverse events by arm: full analysis population
| Adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
|---|---|---|---|
| Diarrhea | “10 (12)” | “8 (10)” | “1 (1)” |
| Fatigue | “11 (13)” | “3 (4)” | “8 (10)” |
| Nausea | “7 (8)” | “8 (10)” | “3 (4)” |
| Weight gain | “7 (8)” | “8 (10)” | “0” |
| Peripheral edema | “7 (8)” | “5 (6)” | “2 (2)” |
| Headache | “7 (8)” | “4 (5)” | “4 (5)” |
| Abdominal pain | “5 (6)” | “4 (5)” | “4 (5)” |
| Dizziness | “6 (7)” | “2 (2)” | “3 (4)” |
| Anemia | “6 (7)” | “1 (1)” | “0” |
| Constipation | “5 (6)” | “3 (4)” | “6 (7)” |
| Increase in aminotransferase level | “3 (4)” | “5 (6)” | “1 (1)” |
Serious adverse events by arm: full analysis population
| Other serious adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
|---|---|---|---|
| Wrist fracture | “0” | “0” | “1 (1)” |
| Unstable angina | “1 (1)” | “0” | “0” |
| Heart failure | “0” | “0” | “1 (1)” |
| Gastroenteritis | “1 (1)” | “0” | “0” |
| Pyelonephritis | “1 (1)” | “0” | “0” |
| Pancreatitis | “0” | “1 (1)” | “0” |
| Undifferentiated connective tissue disease | “0” | “1 (1)” | “0” |
| Urticaria | “0” | “0” | “1 (1)” |
| Foot operation | “1 (1)” | “0” | “0” |
Discontinuations and severe adverse events
Peripheral edema: character, management, and sex of participants with drug-related cases, company presentation
Body weight: mean change from baseline at week 24
Body weight: distribution of weight change at end of treatment, pooled lanifibranor arms
“patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight change showed considerable interindividual variability: at EOT, 51% of patients in pooled lanifibranor arms had stable weight (≤2.5% increase), 16% had moderate increase (2.5−5%), and 33% had ≥5% increase from baseline; with placebo 84% had stable weight, but 16% had >2.5% weight increase (Supplementary Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body weight: weight change category at week 24 by arm, completers, congress poster
| Weight at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
|---|---|---|---|---|
| Number of participants | “73” | “71” | “73” | “144” |
| Stable (2.5% or less) | “61 (84%)” | “41 (58%)” | “32 (44%)” | “73 (51%)” |
| Increase (more than 2.5%), placebo only | “12 (16%)” | “–” | “–” | “–” |
| Increase (2.5% to 5%) | “–” | “9 (13%)” | “14 (19%)” | “23 (16%)” |
| Increase (more than 5%) | “–” | “21 (30%)” | “27 (37%)” | “48 (33%)” |
Anemia and hemoglobin
Heart failure and NT-proBNP
“N-terminal pro b-type natriuretic peptide (NT-proBNP) increased with both lanifibranor doses; AMD at EOT was 8.4 pmol/L (71 pg/mL) with lanifibranor 1200 mg and 4.0 pmol/L (34 pg/mL) with 800 mg (Table 1, Fig. 1J), this increase being correlated with weight increase (Supplementary Table 4, Fig. 3G).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events: registry results
| Serious adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/83 (0.00%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Total serious adverse events | “7/83 (8.43%)” | “3/83 (3.61%)” | “3/81 (3.70%)” |
| Angina unstable | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Cardiac failure | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Pancreatitis | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Pneumobilia | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Gastroenteritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Pyelonephritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Post procedural haematoma | “2/83 (2.41%)” | “1/83 (1.20%)” | “1/81 (1.23%)” |
| Post procedural haemorrhage | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Procedural pain | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Wrist fracture | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Undifferentiated connective tissue disease | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Urticaria | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Foot operation | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
Other adverse events at the 5% reporting threshold: registry results
| Other adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
|---|---|---|---|
| Total | “60/83 (72.29%)” | “48/83 (57.83%)” | “30/81 (37.04%)” |
| Diarrhoea | “10/83 (12.05%)” | “8/83 (9.64%)” | “1/81 (1.23%)” |
| Nausea | “7/83 (8.43%)” | “8/83 (9.64%)” | “3/81 (3.70%)” |
| Constipation | “5/83 (6.02%)” | “3/83 (3.61%)” | “6/81 (7.41%)” |
| Fatigue | “11/83 (13.25%)” | “3/83 (3.61%)” | “8/81 (9.88%)” |
| Oedema peripheral | “7/83 (8.43%)” | “5/83 (6.02%)” | “2/81 (2.47%)” |
| Viral upper respiratory tract infection | “3/83 (3.61%)” | “3/83 (3.61%)” | “5/81 (6.17%)” |
| Weight increased | “7/83 (8.43%)” | “8/83 (9.64%)” | “0/81 (0.00%)” |
| Transaminases increased | “3/83 (3.61%)” | “5/83 (6.02%)” | “1/81 (1.23%)” |
| Headache | “7/83 (8.43%)” | “4/83 (4.82%)” | “4/81 (4.94%)” |
| Dizziness | “6/83 (7.23%)” | “2/83 (2.41%)” | “3/81 (3.70%)” |
Study limitations
Summary: duration, sample size, histology reading, and sponsor role
- Treatment lasted 24 weeks; the protocol states that 6 months is sufficient in a proof-of-concept study and limits the time on placebo.
- The protocol planned 225 randomized participants (75 per arm) for at least 80% power with a two-sided alpha of 0.025, assuming a placebo responder rate of 10% and an excess responder rate of 20%. The placebo response on the primary endpoint was 33% in the multiple imputation analysis of the journal report and 27% in the intention-to-treat population of the company topline release. A total of 247 participants were randomized (83, 83, and 81) out of 868 screened.
- All biopsy samples were read by one pathologist who was unaware of timing and group assignment.
- No fibrosis-stage inclusion criterion was set other than exclusion of cirrhosis; 188 participants (76%) had stage F2 or F3 fibrosis, and results in this group come from a subgroup analysis.
- The journal report states that the validity of the SAF-A score as a surrogate for long-term outcomes “warrants further study”, and that changes in noninvasive biomarkers should be interpreted with caution, “particularly in short-term trials”.
- The sponsor designed the trial, monitored the sites, collected the data, and analyzed the data.
Summary: missing biopsies, analysis methods, protocol changes, and figures that differ by source
- Week 24 biopsies were missing for 34 participants (11 at 800 mg, 9 at 1200 mg, and 14 with placebo). The protocol specified that an amendment would be submitted to increase the sample size if end-of-study slides were unavailable or uninterpretable in more than 5% of participants.
- The protocol's primary rule counted missing data as nonresponse; the journal report's primary analysis used multiple imputation. With multiple imputation, the primary endpoint was met by 55% with 1200 mg and 48% with 800 mg versus 33% with placebo (P=0.007 and P=0.07). The company topline release (intention-to-treat, all randomized) gives 49% (P=0.004) and 41% (P=0.061) versus 27%, and the registry, counting missing data as nonresponse, gives 41 of 83, 34 of 83, and 22 of 81 responders. The journal report states that nonresponder imputation and complete-case results were similar.
- No multiplicity adjustments were defined for secondary and exploratory end points. The cardiometabolic analyses of Cooreman et al. had no multiplicity adjustment, are considered exploratory, and include post hoc analyses.
- Protocol version 5.0, dated July 9, 2019, updated the secondary endpoints. The registry states that the last participant was recruited in March 2019, and the journal report gives a screening period of February 2017 through July 2019.
- The selection period is 3 days to 4 weeks in the protocol and 10 days to 4 weeks in the registry.
- Discontinuations for adverse events are 3 (4%), 4 (5%), and 3 (4%) in the journal report (1200 mg, 800 mg, placebo) and 3, 3, and 3 in the registry participant flow, which lists one further 800 mg participant under “Withdrawal by patient and adverse event non fatal”.
Summary: enrolled population and generalizability
- Of 247 participants, 232 (94%) were White and 103 (42%) had type 2 diabetes. By registry region of enrollment, 55 were enrolled in Bulgaria, 39 in France, and 36 in the United States.
- The protocol required GLP-1 receptor agonists, vitamin E, fibrates, and PPAR gamma agonists to be stopped before randomization, and the registry excluded participants with type 2 diabetes on insulin, HbA1c >8.5%, or body mass index >45 kg/m2.
- Cooreman et al. state that participants who meet study entry criteria may not represent all patients seen in varying practice environments.